Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Docetaxel 391 pembrolizumab 327 Prednisone 285 Gemcitabine 273 enzalutamide 256 Radiotherapy 251 Nivolumab 248 Magnetic Resonance Spectroscopy 247 Cisplatin 209 Abiraterone Acetate 198 Radiosurgery 184 Leuprolide 182 Sunitinib 169 Carboplatin 161 bicalutamide 148 Goserelin 145 Androgen Antagonists 142 Specimen Handling 138 Ipilimumab 128 Paclitaxel 125 Cyclophosphamide 117 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110 Bevacizumab 109 Everolimus 107 abiraterone 100 apalutamide 99 cabozantinib 98 atezolizumab 97 Sorafenib 97 Radiation 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × lortalamine × Genitourinary × Clear all

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡